2024-09-28 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes treatments for life-threatening diseases. 

**1. Performance vs. S&P 500:**

* **Cumulative Return:** GILD: -13.66%, VOO (S&P 500): 134.22%.
* **Performance Gap:** GILD is significantly lagging behind the S&P 500 with a cumulative return difference of -147.88%.
* **Relative Divergence:** The current performance gap sits at the 5.03% percentile of its historical range, indicating GILD is performing significantly worse than the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $83.04
* **5-Day Moving Average:** $83.35
* **20-Day Moving Average:** $81.68
* **60-Day Moving Average:** $76.32
* **Analysis:** The price is currently above all three moving averages, suggesting a potential short-term bullish trend. However, the relatively small difference between the closing price and the 5-day moving average suggests a possible pullback. 

**3. Technical Indicators:**

* **RSI:** 70.77 -  Suggests the stock is in overbought territory, indicating potential for a short-term pullback.
* **PPO:** -0.25 - A negative value suggests a potential bearish trend, but the relatively small magnitude indicates a weak signal.
* **Delta_Previous_Relative_Divergence:** -1.08 (negative) - Indicates a recent short-term downtrend in relative performance.
* **Expected Return:** 0.0% -  The model estimates no significant return over the next 5 years.

**4. Recent Earnings & Outlook:**

| Date      | EPS     | Revenue       |
|-----------|---------|----------------|
| 2024-08-08 | 1.29    | $6.95 Billion  |
| 2024-05-08 | -3.34   | $6.69 Billion  |
| 2023-11-07 | 1.75    | $7.05 Billion  |
| 2023-08-04 | 0.84    | $6.60 Billion  |
| 2024-08-08 | 0.84    | $6.60 Billion  |

**Analysis:**
* **Latest earnings (2024-08-08):** EPS of 1.29 beat analysts' estimates, showing positive performance. 
* **Overall Trend:** While the recent earnings are positive, GILD's earnings have been inconsistent, fluctuating between strong and weak performances. This indicates potential challenges in maintaining growth. 

**5. News & Recent Issues:**

* **Recent Market Outlook:** GILD has been impacted by a slowdown in its core HIV business and competition in its oncology segment. However, the company has been focusing on developing new treatments and potential blockbuster drugs in areas like NASH and cell therapy.
* **Analyst Opinions:** Analysts remain divided on GILD's outlook. Some are optimistic about its pipeline and potential for future growth, while others remain concerned about its current challenges and future competition. 
* **Performance Highlights:** GILD has faced investor skepticism due to its slower growth rate compared to other companies in the pharmaceutical sector. The company has also been criticized for its high drug pricing.

**6. Overall Analysis:**

Gilead Sciences currently faces challenges in its core business, with slower growth and competition in several sectors.  While it has a promising pipeline of new drugs and technologies, investor sentiment remains cautious due to inconsistent earnings and past performance. The stock's technical indicators suggest potential short-term volatility, with a slight bias towards a possible pullback. 

**7. Summary:**

GILD's stock performance has significantly lagged behind the S&P 500, and its recent earnings, while positive, have been inconsistent.  The company's future success will depend on its ability to successfully develop and launch new drugs and therapies. While the stock might see some short-term volatility, the long-term outlook remains uncertain, and investors should carefully consider these factors before making any investment decisions. 
